An update to my column yesterday about Aerie Pharmaceuticals (AERI) and what I called an under-appreciated manufacturing risk related to its glaucoma drug Rhopressa, now under review at the FDA.
It now looks like I over-appreciated the Rhopressa manufacturing challenge.
About the Author Reprints
Get rid of short shill Adam FEURSTEIN Or lose business
This guy is a known basher of great companies
He’s a shill for short hedge funds
Why didn’t you check his background?
STAT better be smart
You guys are gonna lose subscribers